Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Poly‐GP in cerebrospinal fluid links C9orf72‐associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD

Open access

Abstract

The C9orf72 GGGGCC repeat expansion is a major cause of amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD).Non-conventional repeat translation results in five dipeptide repeat proteins (DPRs), but their clinical utility, overall significance, and temporal course in the pathogenesis of c9ALS/FTD are unclear, although animal models support a gain-of-function mechanism.Here, we established a poly-GP immunoassay from cerebrospinal fluid (CSF) to identify and characterize C9orf72 patients.Significant poly-GP levels were already detectable in asymptomatic C9orf72 mutation carriers compared to healthy controls and patients with other neurodegenerative diseases.The poly-GP levels in asymptomatic carriers were similar to symptomatic c9ALS/FTD cases.Poly-GP levels were not correlated with disease onset, clinical scores, and CSF levels of neurofilaments as a marker for axonal damage.Poly-GP determination in CSF revealed a C9orf72 mutation carrier in our cohort and may thus be used as a diagnostic marker in addition to genetic testing to screen patients.Presymptomatic expression of poly-GP and likely other DPR species may contribute to disease onset and thus represents an alluring therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201607486

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Validation of a novel poly‐GP‐specific immunoassay AImmunohistochemistry of frontal cortex from ALS/FTD cases with or without C9orf72 repeat expansion using poly‐GP antibodies 18H8 and 3F9. Both antibodies detect neuronal cytoplasmic inclusions specifically in the C9orf72 case (arrows). Hybridoma supernatants were used at 1:250 dilution as described previously (Schludi et al, 2015). Scale bar 20 μm.B, CPoly‐GP sandwich immunoassay with anti‐GP antibodies 18H8 and 3F9 detects purified GST‐GP15 below 0.03 ng/ml (B), but no other 15‐mer DPRs fused to GST at 1 μg/ml. Data are shown as mean ± SD (n = 2) (C). A four‐parameter logistic curve was used to fit the dose–response using Prism 7.01 software.
Figure 1 Validation of a novel poly‐GP‐specific immunoassay AImmunohistochemistry of frontal cortex from ALS/FTD cases with or without C9orf72 repeat expansion using poly‐GP antibodies 18H8 and 3F9. Both antibodies detect neuronal cytoplasmic inclusions specifically in the C9orf72 case (arrows). Hybridoma supernatants were used at 1:250 dilution as described previously (Schludi et al, 2015). Scale bar 20 μm.B, CPoly‐GP sandwich immunoassay with anti‐GP antibodies 18H8 and 3F9 detects purified GST‐GP15 below 0.03 ng/ml (B), but no other 15‐mer DPRs fused to GST at 1 μg/ml. Data are shown as mean ± SD (n = 2) (C). A four‐parameter logistic curve was used to fit the dose–response using Prism 7.01 software.CC BY · PubMed Central
Figure EV1 The poly‐GP immunoassay is reproducible A–DPoly‐GP sandwich immunoassay with anti‐GP antibodies 18H8 and 3F9 was used to analyze the GST‐GP15 standard at four concentrations. Background‐corrected absolute values, mean, and standard deviation (SD) for n = 4 GST‐GP15 intra‐plate replicates (A), n = 3 inter‐plate replicates (B), and n = 3 day‐to‐day replicates (C). Mean, SD, and the coefficient of variance (CV) for all conditions are listed in (D).
Figure EV1 The poly‐GP immunoassay is reproducible A–DPoly‐GP sandwich immunoassay with anti‐GP antibodies 18H8 and 3F9 was used to analyze the GST‐GP15 standard at four concentrations. Background‐corrected absolute values, mean, and standard deviation (SD) for n = 4 GST‐GP15 intra‐plate replicates (A), n = 3 inter‐plate replicates (B), and n = 3 day‐to‐day replicates (C). Mean, SD, and the coefficient of variance (CV) for all conditions are listed in (D).CC BY · PubMed Central
Figure 2 Poly‐GP expression is increased in CSF of asymptomatic and symptomatic C9orf72 mutation carriers APoly‐GP was measured using immunoassay in an age‐matched control population without signs of a neurodegenerative disease (ND‐CON, n = 18–20), C9orf72‐negative offspring of C9orf72 mutation carriers (NonC9‐F1, n = 8) in patients with other neurodegenerative diseases, that is, Alzheimer's (AD, n = 24) and Parkinson's disease (PD, n = 14), sporadic ALS (sALS, n = 18) and FTD (sFTD, n = 11) patients, and asymptomatic (C9‐F1, n = 10) and symptomatic C9orf72 mutation carriers with ALS (c9ALS, n = 9) and FTD (c9FTD, n = 11). The c9FTD patient indicated by the filled, red circle was initially seen under the differential diagnosis of AD, but after poly‐GP measurement followed by C9orf72 genotyping reclassified as c9FTD.BReceiver operating characteristic (ROC) curve analysis of poly‐GP levels for the discrimination of C9orf72 mutation carriers vs. non‐carriers. The cutoff (43.5) was calculated using the Youden index and is shown as a dotted line in (A). AUC, area under the curve; Sens, sensitivity; Spec, specificity.C, D(C) Phosphorylated neurofilament heavy chain (pNfH) and (D) neurofilament light chain (NfL) were measured using an established ELISA.Data information: Groups were compared by Kruskal–Wallis test and Dunn's post hoc test. Bars and whiskers are median and interquartile range, and circles are individual values. Exact P‐values poly‐GP (A): ND‐CON vs. c9FTD: P = 0.0477; PD vs. AD: P = 0.0053; ND‐CON vs. c9ALS: P = 0.0483; ND‐CON vs. C9‐F1: P = 0.0236; NonC9‐F1 vs. c9FTD: P = 0.0365; NonC9‐F1 vs. c9ALS: P = 0.0334; NonC9‐F1 vs. C9‐F1: P = 0.0194; sALS vs. c9FTD: P = 0.0006; sALS vs. c9ALS: P = 0.0007; sALS vs. C9‐F1: P = 0.0003; sFTD vs. c9FTD, sFTD vs. c9ALS, sFTD vs. C9‐F1, PD vs. c9FTD, PD vs. c9ALS, and PD vs. C9‐F1: P < 0.0001. Exact P‐values pNfH (C): PD vs. C9‐F1: P = 0.0121; PD vs. NonC9‐F1: P = 0.0261; sALS vs. ND‐CON: P = 0.0103; C9‐F1 vs. AD: P = 0.0334; ND‐CON vs. c9ALS: P = 0.0142; NonC9‐F1 vs. c9ALS, C9‐F1 vs. c9ALS, sALS vs. C9‐F1, and sALS vs. NonC9‐F1: P < 0.0001. Exact P‐values NfL (D): sFTD vs. C9‐F1: P = 0.0013; sFTD vs. NonC9‐F1: P = 0.0038; PD vs. C9‐F1: P = 0.0122; PD vs. NonC9‐F1: P = 0.0245; c9ALS vs. AD: P = 0.0107; sALS vs. ND‐CON: P = 0.0017; sALS vs. NonC9‐F1: P = 0.0001; sALS vs. C9‐F1, ND‐CON vs. c9ALS, NonC9‐F1 vs. c9ALS, and C9‐F1 vs. c9ALS: P < 0.0001.
Figure 2 Poly‐GP expression is increased in CSF of asymptomatic and symptomatic C9orf72 mutation carriers APoly‐GP was measured using immunoassay in an age‐matched control population without signs of a neurodegenerative disease (ND‐CON, n = 18–20), C9orf72‐negative offspring of C9orf72 mutation carriers (NonC9‐F1, n = 8) in patients with other neurodegenerative diseases, that is, Alzheimer's (AD, n = 24) and Parkinson's disease (PD, n = 14), sporadic ALS (sALS, n = 18) and FTD (sFTD, n = 11) patients, and asymptomatic (C9‐F1, n = 10) and symptomatic C9orf72 mutation carriers with ALS (c9ALS, n = 9) and FTD (c9FTD, n = 11). The c9FTD patient indicated by the filled, red circle was initially seen under the differential diagnosis of AD, but after poly‐GP measurement followed by C9orf72 genotyping reclassified as c9FTD.BReceiver operating characteristic (ROC) curve analysis of poly‐GP levels for the discrimination of C9orf72 mutation carriers vs. non‐carriers. The cutoff (43.5) was calculated using the Youden index and is shown as a dotted line in (A). AUC, area under the curve; Sens, sensitivity; Spec, specificity.C, D(C) Phosphorylated neurofilament heavy chain (pNfH) and (D) neurofilament light chain (NfL) were measured using an established ELISA.Data information: Groups were compared by Kruskal–Wallis test and Dunn's post hoc test. Bars and whiskers are median and interquartile range, and circles are individual values. Exact P‐values poly‐GP (A): ND‐CON vs. c9FTD: P = 0.0477; PD vs. AD: P = 0.0053; ND‐CON vs. c9ALS: P = 0.0483; ND‐CON vs. C9‐F1: P = 0.0236; NonC9‐F1 vs. c9FTD: P = 0.0365; NonC9‐F1 vs. c9ALS: P = 0.0334; NonC9‐F1 vs. C9‐F1: P = 0.0194; sALS vs. c9FTD: P = 0.0006; sALS vs. c9ALS: P = 0.0007; sALS vs. C9‐F1: P = 0.0003; sFTD vs. c9FTD, sFTD vs. c9ALS, sFTD vs. C9‐F1, PD vs. c9FTD, PD vs. c9ALS, and PD vs. C9‐F1: P < 0.0001. Exact P‐values pNfH (C): PD vs. C9‐F1: P = 0.0121; PD vs. NonC9‐F1: P = 0.0261; sALS vs. ND‐CON: P = 0.0103; C9‐F1 vs. AD: P = 0.0334; ND‐CON vs. c9ALS: P = 0.0142; NonC9‐F1 vs. c9ALS, C9‐F1 vs. c9ALS, sALS vs. C9‐F1, and sALS vs. NonC9‐F1: P < 0.0001. Exact P‐values NfL (D): sFTD vs. C9‐F1: P = 0.0013; sFTD vs. NonC9‐F1: P = 0.0038; PD vs. C9‐F1: P = 0.0122; PD vs. NonC9‐F1: P = 0.0245; c9ALS vs. AD: P = 0.0107; sALS vs. ND‐CON: P = 0.0017; sALS vs. NonC9‐F1: P = 0.0001; sALS vs. C9‐F1, ND‐CON vs. c9ALS, NonC9‐F1 vs. c9ALS, and C9‐F1 vs. c9ALS: P < 0.0001.CC BY · PubMed Central
Figure 3 Poly‐GP expression in CSF correlates neither with markers of neurodegeneration nor with clinical disease severity A–FCorrelation analysis of poly‐GP levels in CSF of c9ALS (A, C, E) and c9FTD cases (B, D, F). Correlation with phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) (A, B), with disease duration at lumbar puncture (LP) and the ALSFRS‐R or FTLD‐CDR score (C, D) and with age at disease onset (E, F).GCorrelation of poly‐GP levels in CSF with the largest repeat length estimated by Southern blotting.HAssociation of poly‐GP levels in CSF with disease duration at LP in c9ALS/FTD patients and with time to expected disease onset in C9‐F1 cases. Time to expected disease onset was calculated using parental age at disease onset.Data information: Correlation analysis was performed using Spearman’s rank correlation coefficient.
Figure 3 Poly‐GP expression in CSF correlates neither with markers of neurodegeneration nor with clinical disease severity A–FCorrelation analysis of poly‐GP levels in CSF of c9ALS (A, C, E) and c9FTD cases (B, D, F). Correlation with phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) (A, B), with disease duration at lumbar puncture (LP) and the ALSFRS‐R or FTLD‐CDR score (C, D) and with age at disease onset (E, F).GCorrelation of poly‐GP levels in CSF with the largest repeat length estimated by Southern blotting.HAssociation of poly‐GP levels in CSF with disease duration at LP in c9ALS/FTD patients and with time to expected disease onset in C9‐F1 cases. Time to expected disease onset was calculated using parental age at disease onset.Data information: Correlation analysis was performed using Spearman’s rank correlation coefficient.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 118

Metadata

Authors
Lehmer, C., Oeckl, P., Weishaupt, J. H., Volk, A. E., Diehl‐Schmid, J., Schroeter, M. L., Lauer, M., Kornhuber, J., Levin, J., Fassbender, K., Landwehrmeyer, B., German Consortium for Frontotemporal Lobar Degeneration, Schludi, M. H., Arzberger, T., Kremmer, E., Flatley, A., Feederle, R., Steinacker, P., Weydt, P., Ludolph, A. C., Edbauer, D., Otto, M., Danek, A., Feneberg, E., Anderl‐Straub, S., von Arnim, C., Jahn, H., Schneider, A., Maler, M., Polyakova, M., Riedl, L., Wiltfang, J., & Ziegler, G.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • University Hospital Ulm (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Technical University of Munich (DE)
  • University Hospital Leipzig (DE)
  • Universitätsklinikum Würzburg (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Saarland University (DE)
  • Helmholtz Munich (DE)
  • University Hospital Bonn (DE)
Corresponding author
  • Edbauer, Dieter
  • Otto, Markus
Venue
EMBO Molecular Medicine
Published
2017-04-13
Volume
9
Issue
7
Pages
859-868
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2606980242
Cited by
118
References
41
Citations by year
2026: 3 · 2025: 10 · 2024: 13 · 2023: 17 · 2022: 17 · 2021: 9 · 2020: 11 · 2019: 15 · 2018: 19 · 2017: 4
FWCI
9.34
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • Site cant be reached (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, other-oa)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
Funders
  • JPND Networks SOPHIA (01ED1202A)
  • BiomarkAPD (01ED1203F)
  • PreFrontAls (01ED1512)
  • STRENGTH (01ED1408)
  • EU (246513, 633190, 617198)
  • German Research Foundation/DFG (VO2028)
  • Baden‐Württemberg (D.3830)
  • BIU (D.5009)
  • Charcot Foundation
  • NOMIS Foundation
  • Seventh Framework Programme (617198)
  • Bundesministerium für Bildung und Forschung (O1GI1007A, 01GM1103A)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
C9orf72, GGGGCC repeat expansion, dipeptide repeat proteins, cerebrospinal fluid biomarkers, amyotrophic lateral sclerosis, frontotemporal dementia, presymptomatic carriers, gain-of-function mechanism, disease onset, neurofilaments, immunoassay
MeSH terms
C9orf72 Protein, Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Cross-Sectional Studies, Dipeptides, Humans, Immunoassay, Peptides, Biomarkers, Gene Expression, Repetitive Sequences, Amino Acid, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Poly‐GP in cerebrospinal fluid links C9orf72‐associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. https://app.cochat.ai/papers/10.15252/emmm.201607486
The paper
Lehmer, C., Oeckl, P., Weishaupt, J. H., Volk, A. E., Diehl‐Schmid, J., Schroeter, M. L., Lauer, M., Kornhuber, J., Levin, J., Fassbender, K., Landwehrmeyer, B., German Consortium for Frontotemporal Lobar Degeneration, Schludi, M. H., Arzberger, T., Kremmer, E., Flatley, A., Feederle, R., Steinacker, P., Weydt, P., . . . Ziegler, G. (2017). Poly‐GP in cerebrospinal fluid links C9orf72‐associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201607486

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.